Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
This study is assessing the efficacy and safety of NPX-5 in psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to cancer diagnosis. Who is it for? This study is for people who are aged between 18 and 80 years old and suffer from anxiety after adjusting to an acutely stressful event of their cancer diagnosis. This is called adjustment disorder. (The sponsor's summary, shortened.)
Eligibility and contacts on ClinicalTrials.govThe registry record
- Status
- Recruiting
- Phase
- Phase 2
- Conditions
- Adjustment Disorder; Adjustment Disorder With Anxious Mood; Cancer; Cancer Cachexia; Cancer of Endometrium; Cancer of Kidney; Cancer of Prostate; Cancer of the Breast; Cancer of Stomach; Cancer Melanoma Skin; Cancer Pancreas
- Intervention
- Psilocybin therapy
- Sponsor
- Psyence Australia Pty Ltd
- Ages
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- No
- Enrolment
- 87 people (planned)
- Start
- 1 October 2025
- Primary completion
- 30 December 2026
- Registry last updated
- 3 March 2026
Sites (3)
- Mind Medicine Australia Clinic, Abbotsford, Victoria, Australia (recruiting)
- Paratus Clinical Research Melbourne, Northcote, Victoria, Australia (recruiting)
- Empax Centre, Leederville, Western Australia, Australia (recruiting)
How joining a trial works
- Free to take part
- Trials generally cost participants nothing for the study drug and the study visits, and some pay for travel or time. Check what a study covers on its registry page.
- Screened first
- Every study screens volunteers with questionnaires, medical history and often a physical and psychiatric check. Many people who apply are not enrolled.
- Eligibility is strict
- Common exclusions include a personal or family history of psychosis or bipolar disorder, some heart conditions, pregnancy and certain medications, which you may be asked to stop under medical supervision. Never stop a medication on your own to qualify.
- You may get a placebo
- Many trials compare psilocybin with a placebo or a low dose, and you may not be told which you had until the study ends.
- Contact the study team through the registry
- Each registry record lists the study contacts and sites. We do not republish personal emails or phone numbers; use the link on each trial page.
- Not medical advice
- This is a list of registry records, not a recommendation. Talk to your doctor before applying. Disclaimer · Safety and medications
Source: ClinicalTrials.gov API v2, U.S. National Library of Medicine, read 28 October 2026. Filter: overall status RECRUITING or NOT_YET_RECRUITING; an intervention named psilocybin, psilocin, COMP360 or CYB003. Refreshed weekly; a study's own registry page is always the current record.
Record read from ClinicalTrials.gov API v2, U.S. National Library of Medicine on 28 October 2026. All psilocybin trials